Novo Nordisk Q1 Earnings Beat Expectations Due to Strong Wegovy Demand

Novo Nordisk reported better-than-expected first-quarter earnings in 2026, driven by strong demand for its weight loss pill Wegovy. The Danish drugmaker raised its full-year guidance and saw a 7% rise in stock price following the results.

By Cris Tolomia Wed, May 6, 2026 at 2:40 PM GMT+3 3 min read · Yahoo Finance · May 6, 2026, 11:40 UTC

Novo Nordisk Q1 Earnings Beat Expectations Due to Strong Wegovy Demand

Tickers: $NVO

Topics: earnings report GLP-1 drugs pharmaceuticals Wegovy

Read the full article at Yahoo Finance

More World news

Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC